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with a polycrystalline sample (in contrast to single-crystal 
diffraction, where a single crystal is not necessarily repre- 
sentative of the bulk material being handled in the pharma- 
ceutical workﬂow). Many reviews of SDPD methodologies have 
now been published (Tremayne, 2004; Datta & Grant, 2004; 
David & Shankland, 2008; Cerny & Favre-Nicolin, 2007; Harris, 
2012) and in particular, the IUCr Monograph on Crystallography 
'Structure Determination from Powder Diffraction Data' (David 
et al., 2002) provides a 'powder sample to refined crystal structure' 
view of the process that is still valid today, despite some 
methodological advances in the field.  
This article will look specifically at representative examples of 
pharmaceutical crystal structures (polymorphs, solvates,  
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Solving pharmaceutical crystal structures from powder 
diffraction data is discussed in terms of the methodologies that 
have been applied and the complexity of the structures that have 
been solved. The principles underlying these methodologies are 
summarized and representative examples of polymorph, solvate, 
salt and cocrystal structure solutions are provided, together with 
examples of some particularly challenging structure 
determinations.  
 
Keywords: pharmaceuticals; crystal structure; powder 
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1. Introduction  
The investigation of crystalline materials is an integral part of  
the processes involved in bringing a new drug to market. 
Numerous techniques, including thermal and spectroscopic 
methods, are available to the solid-state analyst; for a com- 
prehensive review of the relative merits and frequency of use of 
such techniques, see Chieng et al. (2011). Organic small- 
molecule drugs are almost invariably crystalline and so it is 
perhaps unsurprising that powder X-ray diffraction (PXRD) is the 
most frequently used analytical method.  
The versatility of PXRD data is demonstrated by its use 
throughout the different stages of the drug manufacturing 
lifecycle (Ivanisevic et al., 2010; Randall et al., 2010; Brittain, 
2001). Its importance as a 'fingerprint' with which to identify specific 
crystallographic phases is evidenced by its central role in high-
throughput physical form screening and its use (either in 
diagrammatic form, or as a series of reﬂection positions) in patents 
designed to protect physical forms. These aspects have been 
reviewed comprehensively elsewhere (Morissette et al., 2004; 
Florence, 2009; Lemmerer et al., 2011). As will be seen, 'structure 
determination from powder diffraction data' (SDPD) can be 
considered as a routine, though not always straightforward, 
approach that has the advantage of dealing  
give the interested pharmaceutical scientist an insight into the  
principles underlying the various methodologies and their range 
of applicability.  
 
 
2. Sample presentation and data collection for crystal  
structure determination  
The outcome of any powder diffraction experiment that has  
crystal structure determination as its ultimate objective should be 
a diffraction pattern that is as representative of the underlying 
crystallographic phase(s) in the sample as possible. Whilst 
reﬂection is the most widely used instrumental PXRD geometry 
within the pharmaceutical industry, permitting easy sample 
presentation and rapid data collection for phase identification, it 
suffers from several disadvantages that render it non-ideal for 
crystal structure determination. In particular, the effect of sample 
transparency and preferred orientation introduce, respectively, 
shifts in the observed diffraction peak positions and systematic 
variations to the observed intensities (Dinnebier & Billinge, 
2008). When crystal structure deter- mination is the ultimate aim, 
PXRD data are ideally collected in transmission with the sample 
loaded in a thin-walled glass capillary and rotated in the incident 
X-ray beam in order to minimize preferred orientation effects and 
give good powder averaging. On a well-aligned diffractometer, 
data collected in this fashion are likely to be highly 
representative of the underlying crystalline phase(s) in the 
sample. The advantages to industry of collecting PXRD data 'in-
house' are consider- able and laboratory-based PXRD is capable 
of tackling  
complex problems (see, for example, x4.5 and x5). In cases  
where higher instrumental resolution or incident X-ray ﬂux  
are required (e.g. very large unit cells, weak diffraction, 
extensively overlapping reﬂections) synchrotron X-ray sources 
offer an increasingly accessible option, with many such sources 
now offering postal-type services where the data collection 
aspects of the diffraction experiment are handled by facility staff.  
Instrumentation and experimental considerations for both 
laboratory-based and synchrotron PXRD have been discussed, 
in detail, elsewhere (David et al., 2002). Whether collecting data 
in the laboratory, or at a synchrotron source, it is often 
advantageous to cool the sample in order to reduce  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  
The molecular structures of tetracycline (upper) and verapamil (lower).  
Internal DoF (torsion angles that are free to rotate) are indicated by an asterisk 
(*). Assuming that the ring conformations are known, the structure of 
tetracycline (32 non-H atoms) can be described by 6 external DoF plus 2 
internal DoF, whilst that of verapamil (33 non-H atoms) requires 6 external 
DoF plus 13 internal DoF. Thus, tetracycline is the much simpler problem to 
tackle using global optimization, as fewer variables need to be determined.  
 
thermal vibration and so boost the intensity of the higher- angle 
reﬂections. Cooling of capillary samples to ca 100 K is 
conveniently achieved using devices that deliver a constant ﬂow 
of temperature-stabilized nitrogen gas. Anisotropic thermal 
expansion of a lattice upon cooling can also be exploited to help 
with indexing and structure-factor extraction (Shankland, David & 
Sivia, 1997).  
 
 
3. Structure complexity and powder diffraction  
In single-crystal diffraction, structural complexity is normally  
thought of in terms of the number of non-H atoms in the 
asymmetric unit of the structure being studied, as this is the 
number of atom positions to be determined in the initial stages of 
structure solution. Whilst this definition is equally valid in the 
case of molecular SDPD, many problems are instead defined in 
terms of the number of degrees of freedom (DoF1) in the structure 
under study. This is a consequence of the way in which many 
molecular crystal structures are solved using global optimization 
methods that attempt to place a three- dimensional (3D) model of 
each component of the asymmetric unit at its correct position, 
orientation and conformation  
within the unit cell (see x4.3). Fig. 1 shows these different  
metrics for two drug molecules with comparable numbers of  
non-H atoms, but markedly different conformational ﬂex-  
 
 
 
ibility. When assessing the complexity of structures that have 
been solved using SDPD, it is wise to consider both metrics.  
Figs. 2-5 assess the development of SDPD over two decades, 
using information derived from the Cambridge Structural 
Database (CSD, Version 5.34 of November 2012; see 
Supplementary materials for CSD search criteria used; Allen, 
2002). In his definitive summary of the CSD, Frank Allen stated 
that 'the number of structures determined from powder diffraction 
data is now 370, a number which is surely set to rise' (Allen, 
2002). Fig. 2 shows this to be the case, with an average of 82 
powder structures per year being added since 2002. Constituting 
only ca 1% of all crystal structures added in the same period, it 
shows SDPD to be a niche application for organic materials. 
That said, as SDPD is normally only brought to bear when 
single crystals are unavailable, it is undoubtedly a key tool for 
fully populating a crystallographic landscape. Fig. 3 shows that 
when assessed in terms of the number of atoms in the asymmetric 
unit of the crystal struc- ture, powder structures span a similar 
range to those solved by all methods, albeit in a much smaller 
overall number. This is encouraging, as it indicates that many of 
the problems that arise when single crystals cannot be obtained 
are tractable using SDPD methods. Fig. 4 shows the complexity 
of mol- ecular structures solved since 1990 and it is interesting to 
note that since the year 2000, the average number of asymmetric 
unit atoms in molecular crystal structures has stayed 
approximately constant at ca 52. In the case of SDPD, the steady 
rise in both the average and the maximum number of atoms 
reﬂects both method development and increasing ambition, with 
SDPD now well placed to tackle problems of ca 50 atom size. Fig. 
5 shows the same structures as those contributing to Fig. 4, but 
cast in terms of the total number of DoF present in the structure. 
Again, it is clear that the average number of DoF in all structures 
reported has plateaued at just over 13 from the year 2000 
onwards and that this is very  
similar to the typical DoF that is now accessible to SDPD.  
 
 
4. Approaches to SDPD  
It is clear from the plots in x3 that the rise in the number of  
crystal structures solved from powder diffraction data began  
in earnest in the late 1990s and that their complexity has been 
slowly, but steadily, rising since that time. This can be attrib- uted 
to both the development and implementation of global 
optimization methods of structure determination and the 
continuing developments in modified direct methods of 
structure determination. The following sections describe both of 
these approaches and, in particular, highlight the reasons why 
global optimization methods have found favour in phar- 
maceutical crystal structure determination.  
 
 
4.1. Key differences between single-crystal and powder  
 
1 
 
The DoF for a molecular organic molecule are subdivided into external DoF  
diffraction data  
(i.e. three positional and three orientational) and internal (i.e. the number of torsion 
angles that are free to rotate). Covalent bond lengths and bond angles are generally 
treated as fixed well-defined quantities and so it is values for the DoF that must be 
determined in order to solve the crystal structure.  
The key differences between single-crystal and powder  
diffraction data have been discussed in detail elsewhere (David 
et al., 2002) and we only summarize them here in  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  
The number of molecular crystal structures deposited each year since  
1990 in the Cambridge Structural Database (CSD). The upper plot is derived 
from all structures whilst the lower plot is derived from only powder 
structures. Note that the plot is based on the November 2012 release of the 
CSD and, therefore, the final total for 2012 will be higher than the value 
plotted here.  
 
Table 1 in terms of their impact upon structure solution. For 
molecular organic materials, typified by relatively low space- 
group symmetry and the absence of heavy atoms, it is acci- dental 
reﬂection overlap and the rapid fall off in scattering  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3  
The number of molecular crystal structures present in the CSD, plotted as  
a function of the total number of atoms (including hydrogen) in the 
asymmetric unit of the structure. The upper plot is derived from all structures 
whilst the lower plot is derived from only powder structures.  
 
chlorine, accurate structure factors may be obtained to near- 
atomic resolution and conventional direct methods of struc- ture 
determination (e.g. SHELXS; Sheldrick, 2008) then used to 
generate an interpretable map. The prototypical example is that of 
the crystal structure of cimetidine form A, solved from  
with increasing diffraction angle that leads to the relatively low 
information content of the powder diffraction pattern.  
 
 
4.2. Conventional and modified direct methods  
Direct methods, the lynchpin of single-crystal X-ray struc-  
ture determination, do not require any a priori knowledge of the 
connectivity or coordination of any of the atoms in the structure 
under study; connectivity is derived from the elec- tron-density 
map that is generated at the end of a structure- factor phasing 
process. The success of the phasing process and the clarity of the 
electron-density map is critically dependent  
1.273 A resolution synchrotron PXRD data (Cernik et al., ˚ 
1991) using the SIR direct-methods package (Burla et al.,  
1989). Modified direct methods of structure determination have 
integrated the core of such direct methods into the process of 
extracting structure factors from PXRD data, with the aim of 
using partial structure information to improve the  
 
 
 
Table 1  
The key differences between single-crystal and powder diffraction data in  
terms of the information content that is relevant to solving molecular organic 
crystal structures.  
upon the accuracy and resolution of those structure factors. As 
such, maps generated from conventional PXRD data are  
 
 
Number of reﬂections  
Single crystal  
 
Thousands  
Powder  
 
Hundreds  
typically of poor quality and hence can be difficult to interpret.  
Of course, there are exceptions; when very high quality data  
Minimum d-spacing  
Accuracy of |F 2|  
< 0.9A ˚  
Very good  
ca 1.3-1.5 A ˚  
Very good to very poor*  
are collected from a sharply diffracting sample, ideally 
containing some strongly scattering atoms, such as sulfur or  
Note: (*) |F 2| estimates will normally be very good for non-overlapping reﬂections at low  
values of 2/ and increasingly poor at higher values of 2/ where diffraction is weaker and  
accidental reﬂection overlap is considerable.  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  
The mean (diamond) and maximum (square) of the total number of  
atoms (including hydrogen) in the asymmetric unit of molecular crystal 
structures deposited each year since 1990 in the CSD. The upper plot is 
derived from all structures; the middle plot shows an expanded view of the 
mean number of atoms for all structures; the lower plot is derived from only 
powder structures.  
 
 
extracted structure factor intensity estimates. This, coupled with 
recent advances in electron density-map generation and 
interpretation, has relaxed the requirements for near-atomic 
resolution data and thus greatly extended the range of 
applicability of direct methods to powder diffraction data, 
obtained from both inorganic and organic materials. Many of 
these methods are implemented in the EXPO program 
(Altomare et al., 1999) from the University of Bari group, 
making it very well suited to dealing with laboratory-based 
PXRD data collected from typical molecular organic mate- rials.  
 
4.3. Global optimization methods  
Global optimization methods are a logical extension of  
trial-and-error methods of crystal structure determination. In trial-
and-error methods, a model of the crystal structure under study is 
constructed2 and the powder pattern calculated from  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5  
The mean (diamond) and maximum (square) total number of degrees of  
freedom in the asymmetric unit of molecular crystal structures deposited each 
year since 1990 in the CSD. The upper plot is derived from all structures; the 
middle plot shows an expanded view of the mean number of degrees of 
freedom for all structures; the lower plot is derived from only powder 
structures.  
 
 
that model is then compared to the observed powder pattern. If 
there is very good agreement between observed and calculated 
patterns (as assessed by, for example, a small profile  
_2 value), then it can be concluded that the model is a good  
description of the underlying crystalline phase in the sample  
and that the crystal structure has been solved. Of course, for a 
typical molecular organic material, there is only an infinitesi- 
mally small chance of guessing the correct atomic positions first 
time; hence the trial-and-error approach, where the initial  
model is adjusted in such as way as to decrease the _2. The  
problem of obtaining the lowest profile _2 in fact equates to that 
of finding the global minimum of a multidimensional _2  
hypersurface that is a function of the DoF in the problem. This  
hypersurface is dominated by local stationary points and, in 
general, as the number of DoF in the optimization increases, it 
becomes more difficult for any given global optimization 
algorithm to locate the global minimum.  
For the purposes of this article, it suffices to say that many  
2 An initial 3D model of each component in the asymmetric unit is typically  different global optimization methods have been successfully  
obtained from existing crystal structures or via the use of molecular drawing/  
modelling software that produces accurate energy-optimized 3D coordinates. The 
asymmetric unit components are then placed in the previously determined unit cell 
in order to construct a trial crystal structure.  
brought to bear on this particular problem and the interested 
reader is referred to both the original articles and various 
reviews for details of how they work (Turner et al., 2000;  
  
  
 
 
Table 2  
A summary of SDPD crystal structures, selected on the basis of pharmaceutical and historical interest. The corresponding molecular structures are  
shown in Fig. 6. Natom = total number of atoms in the asymmetric unit; Nnon-H = total number on non-H atoms in the asymmetric unit; DoF = total number  
of degrees of freedom in the asymmetric unit.  
 
Name  Entry in Fig. 6  Z0  Natom  Nnon-H  DoF  Method  Software  
 
Salicylic acid  a 1 16  10  7 GS  P-RISCON  (Masciocchi et al., 1994)  
Chlorothiazide  b 1 23  17  7 DM  MITHRIL94  (Shankland, David & Sivia, 1997)  
Ibuprofen  c 1 33  15  10  GA  GAP  (Shankland et al., 1998)  
l-Glutamic acid  d 1 19  10  10  LE  - (Turner et al., 2000)  
Remacemide nitrate  e 1 45  24  18  SA  DASH  (Markvardsen et al., 2002)  
Tri-fi-peptide  f 1 94  41  23  SE+SA  Safe  (Brenner et al., 2002)  
Capsaicin  g 1 49  22  15  HMC  - (Markvardsen et al., 2005)  
Baicalein  h 1 30  20  7 CDE-GA  - (Chong & Tremayne, 2006)  
Famotidine  i 1 35  20  13  PM  EXPO  (Burla et al., 2007)  
Caffeine  j 5 120  70  30  SA  TOPAS  (Lehmann & Stowasser, 2007)  
Captopril  k 1 29  14  10  MDM  EXPO  (Altomare et al., 2007)  
Chlorothiazide  b 1 23  17  7 DM  SHELX  (Fernandes et al., 2008)  
Cyheptamide  l 4 132  72  28  SA  DASH  (Florence et al., 2008)  
Tolbutamide  m 1 36  18  13  PS  PeckCryst  (Feng et al., 2009)  
Tolbutamide  m 1 36  18  13  GA  GEST  (Feng & Dong, 2007)  
Capsaicin  g 1 49  22  15  LM  - (Shankland et al., 2010)  
Nifedipine  n 2 86  50  24  SA  ReX  (Bortolotti et al., 2009)  
l-Arginine  o 2 52  24  25  GA  EAGER  (Courvoisier et al., 2012)  
Amodiaquinium dichloride dihydrate  p 1 57  29  30  MDM  EXPO  (Altomare et al., 2012)  
Vorinostat  q 1 39  19  16  SA/PT  FOX  (Puigjaner et al., 2012)  
Amcinonide  r 2 142  72  20  SA  PSSP  (Pagola & Stephens, 2012)  
Diphenhydramine hydrochloride  s 1 42  20  15  LM  TALP  (Vallcorba et al., 2012)  
Verapamil hydrochloride  t 1 73  34  22  HBB-BC  EXPO  (Altomare, Corriero et al., 2013)  
Zopiclone dihydrate  u 1 50  29  16  HY  EXPO  (Altomare, Cuocci et al., 2013)  
Prilocaine  v 1 36  16  12  SA  PowderSolve  (Rietveld et al., 2013)  
Key: CDE = cultural differential evolution; DM = direct methods; GA = genetic algorithm; GS = grid search; HBB-BC = hybrid big bang-big crunch; HMC = hybrid Monte Carlo; HY =  
hybrid methods; LE = Lamarckian evolution; LM = local minimization; MDM = modified direct methods; PM = Patterson methods; PS = particle swarm; PT = parallel tempering; SA = simulated 
annealing; SE = structure envelope.  
 
 
Shankland, David & Csoka, 1997; Harris et al., 2004; Mark-  and global optimization methods. This is a consequence of the 
vardsen et al., 2005; Chong & Tremayne, 2006; Altomare,  maturity of the latter approaches and the availability of soft- 
Corriero et al., 2013; Shankland et al., 2010; Feng et al., 2009;  ware packages implementing them. However, in the specific  
Favre-Nicolin & Cerny, 2002; Vallcorba et al., 2012; Pagola &  
ˇ  ´ case of charge ﬂipping, the requirement for accurate structure  
Stephens, 2010; Feng & Dong, 2007; Le Bail, 2001; Brodski et al., 
2005; Rapallo, 2009; Engel et al., 1999; David et al., 2006; 
Florence et al., 2005). Simulated annealing (Kirkpatrick et al., 
1983) has proven to be the most widely used and successful 
method to date, largely because of its efficacy, ease-of-imple- 
mentation in programmatic form and ease-of-use for the end user, 
i.e. most of the algorithm control parameters can be either preset 
or determined automatically, without user intervention. No 
single global optimization run is guaranteed to find the global 
minimum in a finite time. Accordingly, multiple runs, from 
randomized starting points, are generally required to increase the 
likelihood of locating the global minimum.  
The majority of global optimization methods are amenable to 
parallelization, making it relatively straightforward and efficient 
to execute these multiple runs (Griffin et al., 2009a,b).  
 
 
4.4. Other methods  
A variety of other methods, including charge-ﬂipping (Wu et  
al., 2006; Palatinus, 2013; Oszlanyi & Suto, 2008; Coelho, 2007) and 
molecular replacement (Von Dreele et al., 2000; Margio- laki & 
Wright, 2008; Noguchi et al., 2012), have been used to solve 
organic crystal structures from powder diffraction data. However, 
to date, these methods have not achieved the same impact on 
small-molecule SDPD as modified direct methods  
factors to near-atomic resolution is a significant restriction when 
working with powder diffraction data.  
 
4.5. Representative examples  
Table 2 and Fig. 6 show a representative selection of phar-  
maceutical crystal structures that have been solved using SDPD 
techniques.  
 
 
5. Specific examples of challenging structure  
determinations  
5.1. Carbamazepine-indomethacin (1/1) cocrystal  
The structure of a carbamazepine-indomethacin (1/1) co-  
crystal [CBZ-IND (1/1)], produced by cogrinding CBZ form  
III and -IND, was recently determined directly from PXRD  
data (Majumder et al., 2011). The structure determination was  
moderately challenging in terms of molecular complexity [Z0 = 
1, 71 atoms in the asymmetric unit, with 18 DoF (12 external plus 
6 internal)], but was further complicated by the incomplete 
transformation of starting materials to cocrystal, resulting in a 
room-temperature laboratory PXRD pattern containing 
contributions from the cocrystal, CBZ form III and  
-IND. Knowing the positions of peak contributions from the  
previously determined crystal structures of the starting  
materials, it was possible to index the remaining peaks in the  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6  
The molecular structures of the compounds listed in Table 2, obtained using MarvinSketch 'Name to Structure' (ChemAxon, 2011). A SMILES string for  
each structure, generated using MarvinSketch, is provided as Supplementary materials.  
 
 
pattern and thus determine the unit cell of the novel cocrystal  nated by performing a Pawley refinement of the cocrystal unit 
phase (Table 3). Thereafter, the CBZ form III and -IND  cell in probable space group P21/c, whilst simultaneously  
contributions to the PXRD pattern were effectively elimi-  carrying out a Rietveld refinement of the CBZ form III and  
  
  
  
 
 
Table 3  Table 4  
CBZ-IND (1/1).  CT-DMF2.  
Instrument  Bruker D8 Advance with LynxEye detector  Instrument  Bruker D8 Advance with Braun detector  
Geometry  Capillary (0.7 mm), transmission  Geometry  Capillary (0.7mm), transmission  
Radiation  Cu Kff
1
 (1.54056 A) ˚ Radiation  Cu Kff
1
 (1.54056 A) ˚ 
Temperature  295 K  Temperature  295 K  
Scan range (1) 2/  1 3-22 (2 s/0.0171 step)  Scan range (1) 2/  1 4-15 (3 s/0.0141 step)  
2 22-40 (4 s/0.0171 step)  2 15-25 (6 s / 0.0141 step)  
3 40-55 (15 s/0.0171 step)  3 25-35 (14 s / 0.0141 step)  
4 55-70 (24 s/0.0171 step)  4 35-50 (32 s / 0.0141 step)  
Crystal system/space group  Monoclinic, P21/c  5 50-70 (64 s / 0.0141 step)  
a, b, c (A) ˚ 10.2447 (3), 29.148 (1), 10.2114 (3)  Crystal system/space group  Monoclinic, P21/c  
fi (1 )  
Volume (A3) ˚ 
106.636 (2)  
2921.6 (2)  
a, b, c (A) ˚ 
fi (1 )  
12.3586 (2), 8.5619 (2), 37.3043 (7)  
92.8786 (13)  
SA runs  
Final Rwp Pawley  
Final Rwp Rietveld  
Asymmetric unit of crystal  
100 runs of 5 Â 106 SA moves; 4 solutions  
1.58  
3.99  
Volume (A3 ˚ 
SA runs  
Final Rwp Pawley (2-65
1)  
Final Rwp Rietveld (2-65
1)  
Asymmetric unit of crystal  
3942.30 (13)  
99 runs of 800 Â 106 SA moves; 4 solutions  
1.55  
2.03  
 
 
 
 
 
 
 
 
 
 
 
 
 
two molecules of DMF per CT, but also Z0 = 2 3. Thus, the  
structure determination was extremely challenging in terms of 
molecular complexity [94 atoms in the asymmetric unit, with 42 
DoF (36 external plus 6 internal)] and further complicated  
-IND crystal structures. The outcome of this process was a  
PXRD pattern containing only the scattering contribution  
from the cocrystal. Thereafter, SDPD using DASH (David et al., 
2006) proceeded routinely. The solved structure was refined 
against the original PXRD data using a multiphase  
(cocrystal, CBZ form III, -IND) rigid-body-type Rietveld  
refinement in TOPAS (Coelho, 2003). This analysis highlights  
two very important points: (i) with grinding/milling experi- 
ments, where the production of crystals suitable for single- 
crystal diffraction is unlikely, it is still possible to obtain a crystal 
structure using SDPD; (ii) the presence of 'contam- inating' 
crystalline phases (starting materials, transformed starting 
materials) need not preclude high-quality crystal structure 
determination.  
 
 
5.2. Chlorothiazide dimethylformamide solvate (CT-DMF2)  
The crystal structure of a dimethylformamide (DMF)  
solvate of the diuretic compound chlorothiazide (CT) was solved 
directly from PXRD data (Fernandes et al., 2007). The 
compound, crystallized by slow evaporation of a saturated 
solution of DMF over a period of three months, was loaded  
by the solvent contribution to the PXRD pattern background. 
Nevertheless, the structure was solved using DASH, with a large 
number of simulated annealing moves being employed in order to 
increase the likelihood of locating the global minimum in the 
complex structure solution space. With six independent fragments 
in the asymmetric unit, careful Riet- veld refinement of the 
DASH structure was required in order to ensure that the DMF 
molecules, in particular, were correctly positioned and oriented 
to give a chemically sensible hydrogen-bonding network.  
 
 
6. Structure refinement  
Rietveld refinement (Rietveld, 2010) aims to maximize the  
agreement between the calculated and observed powder 
diffraction profiles by adjusting the positions of the atoms from 
the initial solved crystal structure. As a consequence of the 
limited information content of the observed data, however, care 
must be taken to ensure that maximizing this agreement does not 
come at the expense of chemical sense. By way of example, the 
CBZ-IND (1/1) cocrystal structure  
into a 0.7 mm capillary along with a small amount of saturated  (Table 3) solved by SA using data to 501 2/ (1.82 A resolution) ˚ 
DMF solution to prevent desolvation. PXRD data, collected   
3 
 
Estimated molecular volumes (Hofmann, 2002): VCT = 285 A
3; VDMF = 100 A
3;  
˚ ˚ 
at room temperature, indexed to a monoclinic unit cell of  VCT-DMF2 = 485 A3. Vcell/VCT-DMF2 = 8.1; hence Z = 8 and as the space group was ˚ 
volume 3942 A3 (Table 4), suggesting not only the presence of ˚ determined to be P21/c, Z0 = 2.  
  
was refined against data to 651 2/ (1.43 A resolution) using ˚ 
rigid-body descriptions of the CBZ and IND molecules in  
TOPAS (Coelho, 2003) in order to preserve their molecular 
geometries. The resultant high-quality fit to the full data range, 
coupled with the chemically reasonable geometry/crystal 
packing confirms the correctness of the CBZ-IND (1/1) cocrystal 
structure. The CT-DMF2 crystal structure refine- ment (Table 4) 
was approached slightly differently (individual atomic positions 
were refined, subject to a series of restraints on bond lengths, 
bond angles and group planarity), but the end result was the same, 
i.e. a good Rietveld fit to the observed data and a chemically 
reasonable CT-DMF2 crystal structure.  
Looking beyond Rietveld refinement, and considering the 
increasingly large structures being solved using SDPD, peri- odic 
density functional theory calculations are being used 
increasingly to finalize features (particularly H-atom posi- tions) 
in the crystal structure that may not be particularly well defined 
by the diffraction data alone and also to identify  
energetically unrealistic structures (Bruening et al., 2011).  
 
 
7. Publication  
The final step before reporting a refined powder structure is to  
work-up the CIF to an acceptable standard. There are a number 
of helpful tools available, including MOGUL (Bruno et al., 2004) 
for checking geometry and enCIFer (Allen et al., 2004) for 
checking format compliance. A final check on the completed CIF 
is best carried out using the official IUCr structure-validation 
suite checkCIF/PLATON (Spek, 2009), accessible at 
http://journals.iucr.org/services/cif/checking/ checkfull.html. The 
powder CIF dictionary (pdCIF, http:// 
www.iucr.org/resources/cif/dictionaries/cif_pd) contains terms that 
are useful in describing PXRD-specific elements of a CIF, 
including diffraction profile data. Good examples of the correct 
usage of these terms can be found in the deposited CIFs that 
accompany submissions to IUCr journals and are freely available 
to download.  
 
 
8. Outlook  
There is no doubt that SDPD has made a small but highly  
significant contribution to the field of molecular crystal structure 
determination and that pharmaceutical sciences have benefitted 
as a result. Looking to the future, it appears electron 
crystallography is emerging as an exciting comple- ment to 
powder diffraction (McCusker & Baerlocher, 2013; Kolb et al., 
2012) and that their combined use will further extend the range 
of applicability of SDPD to pharmaceuticals.  
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